IL152315A - Soluble mutant ALTC4 molecules and pharmaceutical preparations containing them - Google Patents

Soluble mutant ALTC4 molecules and pharmaceutical preparations containing them

Info

Publication number
IL152315A
IL152315A IL152315A IL15231501A IL152315A IL 152315 A IL152315 A IL 152315A IL 152315 A IL152315 A IL 152315A IL 15231501 A IL15231501 A IL 15231501A IL 152315 A IL152315 A IL 152315A
Authority
IL
Israel
Prior art keywords
ctla4 mutant
mutant molecule
molecule
ctla4
cell
Prior art date
Application number
IL152315A
Other languages
English (en)
Hebrew (he)
Other versions
IL152315A0 (en
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL152315A0 publication Critical patent/IL152315A0/xx
Publication of IL152315A publication Critical patent/IL152315A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL152315A 2000-05-26 2001-05-23 Soluble mutant ALTC4 molecules and pharmaceutical preparations containing them IL152315A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (2)

Publication Number Publication Date
IL152315A0 IL152315A0 (en) 2003-05-29
IL152315A true IL152315A (en) 2010-04-15

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
IL152315A IL152315A (en) 2000-05-26 2001-05-23 Soluble mutant ALTC4 molecules and pharmaceutical preparations containing them

Country Status (41)

Country Link
EP (3) EP1248802B9 (enEXAMPLES)
JP (1) JP4328525B2 (enEXAMPLES)
KR (2) KR100889887B1 (enEXAMPLES)
CN (2) CN1309735C (enEXAMPLES)
AR (1) AR031699A1 (enEXAMPLES)
AT (1) ATE271066T1 (enEXAMPLES)
AU (2) AU6346601A (enEXAMPLES)
BE (1) BE2011C041I2 (enEXAMPLES)
BR (1) BRPI0111191B8 (enEXAMPLES)
CA (1) CA2409748C (enEXAMPLES)
CY (2) CY2011019I1 (enEXAMPLES)
CZ (1) CZ304451B6 (enEXAMPLES)
DE (2) DE60104282T2 (enEXAMPLES)
DK (1) DK1248802T3 (enEXAMPLES)
EC (1) ECSP024365A (enEXAMPLES)
EE (2) EE05458B1 (enEXAMPLES)
EG (1) EG24459A (enEXAMPLES)
ES (2) ES2571852T3 (enEXAMPLES)
FR (1) FR11C0053I2 (enEXAMPLES)
GE (1) GEP20053658B (enEXAMPLES)
HK (1) HK1048126B (enEXAMPLES)
HU (2) HU228137B1 (enEXAMPLES)
IL (1) IL152315A (enEXAMPLES)
LT (1) LT5133B (enEXAMPLES)
LU (1) LU91902I2 (enEXAMPLES)
LV (1) LV12994B (enEXAMPLES)
MX (1) MXPA02011534A (enEXAMPLES)
MY (1) MY136113A (enEXAMPLES)
NO (2) NO330797B1 (enEXAMPLES)
PE (1) PE20011338A1 (enEXAMPLES)
PL (1) PL206267B1 (enEXAMPLES)
PT (1) PT1248802E (enEXAMPLES)
RU (1) RU2283847C2 (enEXAMPLES)
SI (1) SI1248802T1 (enEXAMPLES)
SK (1) SK288131B6 (enEXAMPLES)
TR (1) TR200402703T4 (enEXAMPLES)
TW (2) TWI319405B (enEXAMPLES)
UA (1) UA87432C2 (enEXAMPLES)
UY (1) UY26723A1 (enEXAMPLES)
WO (1) WO2001092337A2 (enEXAMPLES)
ZA (1) ZA200208944B (enEXAMPLES)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
DE60135029D1 (de) 2000-07-03 2008-09-04 Bristol Myers Squibb Co Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
WO2002094202A2 (en) 2001-05-23 2002-11-28 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
EP1496931A4 (en) * 2002-04-19 2009-07-01 Bristol Myers Squibb Co METHODS OF TREATING AUTOIMMUNE DISEASE USING SOLUBLE CTLA4 MOLECULE AND ARMM OR NSAID
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
MXPA05006523A (es) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
KR101088223B1 (ko) 2002-12-23 2011-11-30 브리스톨-마이어스 스큅 컴퍼니 단백질 생산을 위한 포유류 세포 배양 방법에서의 생산물품질 향상
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
CA2836123C (en) 2005-12-20 2017-09-12 Bristol-Myers Squibb Company Compositions and methods for producing a composition
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
CA2832111A1 (en) 2006-12-20 2008-07-03 Mmrglobal, Inc. Antibodies and methods for making and using them
CA2703263C (en) 2007-11-01 2014-03-18 Perseid Therapeutics Llc Immunosuppressive polypeptides and nucleic acids
NO2344540T3 (enEXAMPLES) * 2008-10-02 2018-04-28
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2545073B1 (en) * 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Ctla4 proteins and their uses
EA201370187A1 (ru) 2011-02-23 2013-12-30 Амген Инк. Клеточная культуральная среда для уфс воздействия и относящиеся к ней способы
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
CN104302309B (zh) 2012-05-11 2017-07-28 米迪缪尼有限公司 Ctla‑4变体
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
MX377570B (es) * 2012-06-27 2025-03-10 Orban Biotech Llc Proteínas de fusión ctla4 para el tratamiento de la diabetes.
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
SG11201605640UA (en) 2014-01-13 2016-08-30 Amgen Inc Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
TR201900776T4 (tr) 2014-06-04 2019-02-21 Amgen Inc Memeli hücre kültürlerinin hasadına ilişkin yöntem.
MX385409B (es) 2014-12-01 2025-03-04 Amgen Inc Proceso para manipular el nivel de contenido de glicano de una glicoproteína.
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
PL3283508T3 (pl) 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Białka immunomodulacyjne o dostrajalnym powinowactwie
WO2017044807A2 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
CN108350416A (zh) 2015-11-09 2018-07-31 百时美施贵宝公司 操纵在cho细胞中产生的多肽的品质属性的方法
CN116942793A (zh) 2016-09-19 2023-10-27 昂科医药 Cd80和cd86结合蛋白组合物及其用途
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
MX2019012567A (es) 2017-04-20 2020-02-13 Egenesis Inc Metodos para generar animales geneticamente modificados.
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
US20220281939A1 (en) 2019-08-27 2022-09-08 Tonix Pharma Limited Modified tff2 polypeptides
KR20240007293A (ko) 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
EP4146686A2 (en) 2020-05-08 2023-03-15 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
BR112022024135A2 (pt) 2020-06-18 2022-12-27 Regeneron Pharma Metodologia de peptídeo pesado para medir com precisão lisina c-terminal não processada
WO2022027013A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
KR20240125949A (ko) 2021-12-16 2024-08-20 브리스톨-마이어스 스큅 컴퍼니 바이러스 불활성화를 위한 세제
IL315321A (en) 2022-03-02 2024-10-01 Regeneron Pharma Manufacturing process for high titer antibody

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
WO1993000431A1 (en) * 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
EP1119253A4 (en) * 1998-10-07 2005-12-21 Millennium Pharm Inc NEW SPECIFIC MOLECULES OF Th2 AND USES THEREOF
DE60135029D1 (de) * 2000-07-03 2008-09-04 Bristol Myers Squibb Co Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis

Also Published As

Publication number Publication date
HK1048126A1 (en) 2003-03-21
EP1536234A2 (en) 2005-06-01
KR100895134B1 (ko) 2009-05-04
CN1441810A (zh) 2003-09-10
IL152315A0 (en) 2003-05-29
NO2011027I2 (enEXAMPLES) 2011-12-15
CA2409748C (en) 2008-09-16
CZ20023892A3 (cs) 2003-09-17
UY26723A1 (es) 2001-12-28
HUP0302201A2 (hu) 2003-10-28
PE20011338A1 (es) 2002-01-13
LT5133B (lt) 2004-05-25
TW200906857A (en) 2009-02-16
HUP0302201A3 (en) 2010-01-28
AU6346601A (en) 2001-12-11
DK1248802T3 (da) 2004-11-15
SK15702002A3 (sk) 2004-01-08
CA2409748A1 (en) 2001-12-06
AU2001263466B2 (en) 2006-04-27
ATE271066T1 (de) 2004-07-15
EE201100050A (et) 2011-10-17
SK288131B6 (sk) 2013-10-02
FR11C0053I2 (fr) 2013-01-11
EP1248802B9 (en) 2005-05-11
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
WO2001092337A3 (en) 2002-05-10
FR11C0053I1 (enEXAMPLES) 2012-01-13
HK1071931A1 (en) 2005-08-05
HK1048126B (en) 2005-03-04
WO2001092337A2 (en) 2001-12-06
EP1536234B1 (en) 2016-03-16
CN1309735C (zh) 2007-04-11
TWI314933B (en) 2009-09-21
AR031699A1 (es) 2003-10-01
TR200402703T4 (tr) 2004-11-22
NO20025656L (no) 2002-11-25
MXPA02011534A (es) 2004-08-12
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
BRPI0111191B8 (pt) 2021-05-25
EE200200659A (et) 2004-06-15
ECSP024365A (es) 2003-03-31
HUS1300012I1 (hu) 2016-08-29
BE2011C041I2 (enEXAMPLES) 2020-08-20
LV12994B (en) 2003-08-20
CY1117625T1 (el) 2017-04-26
SI1248802T1 (en) 2005-02-28
ES2571852T3 (es) 2016-05-27
NO20025656D0 (no) 2002-11-25
UA87432C2 (uk) 2009-07-27
GEP20053658B (en) 2005-11-10
EP1248802B1 (en) 2004-07-14
ES2225549T3 (es) 2005-03-16
PT1248802E (pt) 2004-11-30
MY136113A (en) 2008-08-29
TWI319405B (en) 2010-01-11
BRPI0111191B1 (pt) 2019-12-31
BR0111191A (pt) 2004-07-06
LT2002114A (en) 2003-12-29
EP3029062A1 (en) 2016-06-08
HU228137B1 (en) 2012-12-28
EE05557B1 (et) 2012-08-15
DE60104282D1 (de) 2004-08-19
EP1536234A3 (en) 2009-06-03
EE05458B1 (et) 2011-08-15
NO330797B1 (no) 2011-07-18
AU2001263466C1 (en) 2006-10-26
ZA200208944B (en) 2004-02-13
KR100889887B1 (ko) 2009-03-24
CY2011019I1 (el) 2016-12-14
EG24459A (en) 2009-07-16
PL206267B1 (pl) 2010-07-30
DE122011100063I1 (de) 2012-06-14
NO2011027I1 (no) 2012-01-09
JP4328525B2 (ja) 2009-09-09
KR20030009502A (ko) 2003-01-29
CZ304451B6 (cs) 2014-05-14
DE60104282T2 (de) 2005-10-13
PL366231A1 (en) 2005-01-24
RU2283847C2 (ru) 2006-09-20
CN101255192A (zh) 2008-09-03
JP2004511213A (ja) 2004-04-15

Similar Documents

Publication Publication Date Title
IL152315A (en) Soluble mutant ALTC4 molecules and pharmaceutical preparations containing them
RU2002131588A (ru) Растворимый мутантный ctla4 и его применение
JP7637415B2 (ja) インターロイキン－２バリアントおよびその使用方法
EP2844667B1 (en) Targeted/immunomodulatory fusion proteins and methods for making same
AU2013301562B2 (en) Interleukin-2 fusion proteins and uses thereof
JP4787750B2 (ja) Ｃｄ２０結合性ポリペプチド構成物
CN110520445B (zh) 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备
AU640115B2 (en) Cloning and expression of transforming growth factor beta-2
RU2004115039A (ru) Растворимые мутантные молекулы ctla4
RU2006127554A (ru) Fc-эритропоэтин слитый белок с улучшенной фармакокинетикой
CN114728040A (zh) 新型白介素-2变体及其双功能融合分子
CN114051500A (zh) 包含白细胞介素-2突变体和抗cd8抗体的免疫缀合物
KR102247704B1 (ko) 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
WO2019155408A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing same
CA2430135A1 (en) Recombinant anti-cd30 antibodies and uses thereof
JP2023521238A (ja) 免疫複合体
NZ244281A (en) Hybrid recombinant protein coded for by a two part fused sequence comprising a human il-5 dna sequence and an immunoglobulin dna sequence; processes
CA2560278A1 (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
IL130123A (en) LAG-3 protein mutants, their expression, use and method of production
CN111808192A (zh) 结合lag3的抗体及其用途
US20200377588A1 (en) Highly Versatile Method of Presenting Cyclic Peptide on Protein Structure
CN113939534A (zh) 具有降低的断裂的抗αβTCR结合多肽
US20230340054A1 (en) Interleukin-2 muteins and uses thereof
WO1995014779A1 (en) Mutated hig-e fragments and derivative thereof
JP2003529370A5 (enEXAMPLES)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
EXTF Application for patent extension filed
KB Patent renewed
PEL Intention of commissioner to extend period of protection

Free format text: PRODUCT NAME: BELATACEPT

Extension date: 20250615

KB Patent renewed